uniQure NV has presented promising updated results from a Phase IIb trial of its gene therapy AMT-061 for hemophilia B which the Netherlands-headquartered firm believes could be best in class and first to market ahead of Spark Therapeutics Inc. and Pfizer Inc.'s rival candidate.
Initial data released in November demonstrated that after six weeks, three patients receiving AMT-061, an AAV5-based gene therapy which contains...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
